News
The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...
Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...
Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...
Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...
The review, published in Diabetes, Obesity and Metabolism, dissected the rigorous regulatory pathways in the European Union (EU) and the US, ultimately confirming the safety of insulin biosimilars and ...
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and ...
The tumor necrosis factor (TNF)-α inhibitor infliximab is used to treat a variety of immune-mediated inflammatory diseases, including IBD (CD and UC) and RA, in which the cytokine TNF plays a central ...
Biosimilar SB12 or Epysqli (eculizumab-aagh; Samsung Bioepis) is equivalent to reference eculizumab (Soliris) for treating complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results